ARTICLE | Clinical News
Tenofovir alafenamide fumarate: Additional Phase III data
May 2, 2016 7:00 AM UTC
Additional secondary endpoint data from the double-blind, international Phase III Study 110 in 873 hepatitis B e antigen (HBeAg)-positive chronic HBV-infected patients showed that once-daily 25 mg ora...